tiprankstipranks
Advertisement
Advertisement

CH:BIOV Stock Latest News

BioVersys Strengthens Investor Outreach With New IR and Communications Head
Company AnnouncementsBioVersys Strengthens Investor Outreach With New IR and Communications Head
4d ago
BIOV
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
PremiumRatings
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
6d ago
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
PremiumCompany Announcements
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
6d ago
BIOV
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
PremiumCompany Announcements
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
19d ago
BIOV
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
PremiumRatings
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
19d ago
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
PremiumCompany AnnouncementsBioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
21d ago
BIOV
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
Premium
Ratings
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
23d ago
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
Premium
Company Announcements
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
25d ago
BIOV
BioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
PremiumCompany Announcements
BioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
1M ago
BIOV
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
PremiumCompany Announcements
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
1M ago
BIOV
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
PremiumCompany Announcements
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
1M ago
BIOV
BioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
PremiumCompany Announcements
BioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
1M ago
BIOV
BioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
PremiumCompany AnnouncementsBioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
2M ago
BIOV
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
Premium
Company Announcements
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
3M ago
BIOV
BioVersys AG Launches BV100 Phase 3 and Strengthens Market Position
Premium
Company Announcements
BioVersys AG Launches BV100 Phase 3 and Strengthens Market Position
4M ago
BIOV
BioVersys’ BV100 Selected for Phase 2b Trial in Southeast Asia
PremiumCompany Announcements
BioVersys’ BV100 Selected for Phase 2b Trial in Southeast Asia
5M ago
BIOV
BioVersys Initiates Phase 1 Trial of BV100 in China to Combat Drug-Resistant Infections
PremiumCompany Announcements
BioVersys Initiates Phase 1 Trial of BV100 in China to Combat Drug-Resistant Infections
5M ago
BIOV
BioVersys to Present Developments at Stifel 2025 Healthcare Conference
PremiumCompany Announcements
BioVersys to Present Developments at Stifel 2025 Healthcare Conference
5M ago
BIOV
BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer
PremiumCompany Announcements
BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer
5M ago
BIOV
BioVersys AG Reports Key Financials and Clinical Progress for H1 2025
PremiumCompany AnnouncementsBioVersys AG Reports Key Financials and Clinical Progress for H1 2025
7M ago
BIOV
BioVersys AG to Announce Half-Year 2025 Financial Results and Host Conference Call
Premium
Company Announcements
BioVersys AG to Announce Half-Year 2025 Financial Results and Host Conference Call
7M ago
BIOV
BioVersys Secures EMA Orphan Designation for Tuberculosis Treatment
Premium
Company Announcements
BioVersys Secures EMA Orphan Designation for Tuberculosis Treatment
7M ago
BIOV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >